Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2004;328:1259 (22 May), doi:10.1136/bmj.328.7450.1259
| The first 150 words of the full text of this article appear below. |
EDITORThe paper by Plowe et al entitled "Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria" might be better titled "Sustained lack of efficacy of sulfadoxine-pyrimethamine...."1 By the start of the study period five years ago, molecular genotyping showed that Plasmodium falciparum in Malawi had already acquired significant resistance to the combination.1
2 This explains the sustained lack of efficacy; 28 day cure rates in children with acute falciparum malaria remained steadily less than 40% over the five year study period. This is confirmed by the Malawi component of recent WHO-Special Programme for Research and Training in Tropical Diseases (TDR) multicentre trials; the 28 day cure rate with sulfadoxine-pyrimethamine in children with acute falciparum malaria was only 23%,3 and this for a major killing disease of childhood. A 77% failure rate is among the worst responses ever documented. Only 7% (5/71) of reported trials on sulfadoxine-pyrimethamine have had worse
Nicholas White, professor of tropical medicine
Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Rd, Bangkok 10400, Thailand nickw@tropmedres.ac